paroxetine + risperidone

Paroxetine + risperidone is a combination of two pharmaceutical drugs, paroxetine and risperidone, used together primarily in psychiatric settings. Paroxetine is a selective serotonin reuptake inhibitor (SSRI) antidepressant that increases synaptic serotonin levels by inhibiting its reuptake. Risperidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, among others. The combination has been studied for use in conditions such as schizophrenia with prominent negative symptoms and bipolar depression, often as augmentation to mood stabilizers or antipsychotic regimens[1][2]. Coadministration can lead to pharmacokinetic interactions; specifically, paroxetine inhibits CYP2D6-mediated metabolism of risperidone, resulting in increased plasma concentrations of risperidone and potentially greater risk of side effects such as extrapyramidal symptoms or weight gain[1][3][7]. Clinical studies suggest the combination may modestly improve depressive or negative symptoms but requires careful monitoring due to interaction risks.